Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site
Conditions
Interventions
Intervention1: NIL: NIL
Intervention2: Nil: Nil
Control Intervention1: NIL: NIL
Sponsors
Tzar Genomics India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Non cancer (control) individuals 1.Age: 18 yrs and above 2.Individuals with no prior history of cancer. 3.Healthy individuals or Subject who are suffering from comorbidities other than cancer. 4.Subjects who are ready to follow the study design. Cancer individuals: 1.Age:18 yrs and above 2.Newly diagnosed patients, patients on active treatment and cancer survivors. 3.Cancer patients will be confirmed on histopathology irrespective of grade and stage. 4.Subjects who are ready to follow the study design.
Exclusion criteria
Exclusion criteria: 1.Cancer subjects who have received anticancer treatment within 7 days of sample collection (Chemotherapy, radiotherapy, immunotherapy, etc) 2.Non cancer/ control subjects who have severe or life-threatening comorbidities. 3.Subjects who have undergone surgery within previous 2 weeks of sample collection. 4.Subjects who have undergone any blood transfusion or blood donation in the last 2 weeks. 5.Pregnant/ lactating females. 6.Subjects who have received growth factors in past 2 weeks. 7.Verified biohazard samples will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Identification of cancer and non-cancer subjects using biochemical fingerprints of Raman Spectroscopy, expression patterns of ddPCR, qPCR, dPCR and Flow Cytometry. 2.Establishment of a clear, quantitative Systemic Malignancy Score for Cancer (SMAC) to non-invasively stratify individuals into negligible, low/indeterminate, moderate, or high cancer-risk categories. 3.Development of a machine learning based proprietary method leveraging transcriptomic and exomic profiles to accurately distinguish cancer and non-cancer status.Timepoint: Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Longitudinally monitoring risk of cancer occurrence in screening subjects, response to standard treatment in active cancer patients and cancer recurrence in survivors using ddPCR, qPCR, dPCR, Raman Spectroscopy and NGS based platforms. 2.Development of a proprietary method to assess genetic predisposition through monogenic risk score and polygenic risk score. 3.Development of test for MRD evaluation for both liquid and solid cancer.Timepoint: Follow up | — |
Countries
India
Contacts
Public ContactDr Nitu Kumari Jha
Tzar Genomics India Private Limited
Outcome results
None listed